вторник, 27 декабря 2016 г.

Positive Clinical Utility Results of Crescendo's Vectra DA Test for...

Positive Clinical Utility Results of Crescendo's Vectra DA Test for...


SALT LAKE CITY, Dec. 27, 2016 -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced that new data on the use of VectraA DA test to predict treatment response in patients with rheumatoid arthritis published online in the journal Arthritis & Rheumatology .1 "This study highlights the clinical utility of the Vectra DA test to help predict treatment response to biologic and non-biologic therapies in methotrexate incomplete responders," said Elena Hitraya, M.D., Ph.D., chief medical officer, Crescendo Bioscience. "These results showed that Vectra DA performed better than clinical and single inflammatory biomarkers at predicting response to non-biological therapy intensification versus anti-TNF therapy.



from Biotech News